dowling-degos disease is a rare sporadic or autosomal dominant pigmentary entity, in which clusters of papules and reticulate macules slowly develop with predominance in flexural regions. this entity is due to mutations in the keratin 5 gene, and is related with other cutaneous disorders. we report the sporadic form of dowling-degos disease in an elderly man with multiple seborrheickeratosis in...

Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor (TKI) that is approved for the treatment of imatinib-resistant chronic myeloid leukaemia expressing the Bcr-Abl mutation. Cutaneous adverse drug reactions occur more frequently in patients using this medication. We present a case of nilotinib-induced keratosis pilaris that did not have accompanying symptoms of alopecia or prurit...

Please cite this article as: Collgros H, Lamas-Doménech N. FR-Lentigo maligno, actualización en técnicas diagnósticas y terapéuticas. Actas Dermosifiliogr. 2015;106:135--136. ∗ Corresponding author. E-mail address: [email protected] (H. Collgros). Differential diagnosis includes seborrheic keratosis, solar lentigo, lichenoid keratosis, actinic keratosis, and pigmented actinic keratosis. ...

To determine the characteristic pattern and frequency of dermatoses in dermatologic patients over 65 years we used electronic data base of General hospital Karlovac and conducted a retrospective cross sectional study evaluating age, sex and proportion of dermatoses. Total number of patients was 3200. There were 822 (25.69%) patients older than 65 years, and 2378 (74.31%) patients aged from 18-6...

BACKGROUND Current parameters for assessing the efficacy of actinic keratosis (AK) treatments compare clinical lesions at the start and end of a study. However, the sun-exposed field also contains subclinical lesions which may become detectable during treatment. Lmax, the maximum lesion count during treatment, is a new concept to better assess the efficacy of field-directed AK therapies. Measur...

Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area.

A 58 year old man was referred to suegery clinic due to dyspnea and left sided chest wall pain for three months duration.during the last 18 months some monomorph disseminated hyperkeratotic skin lesions appeared on his face and trunk.after worlup and evaluation of the patient,he underwent thoracotomy with indication of presence of a mass in the left lung.the operative finding was a huge solid r...

LeserTrlat syndrome is characterized by the sudden appearance of a large amount elements seborrheic keratosis. The associated with development malignant tumors internal organs. reason for probably production cytokines cells organs (transforming growth factor alpha (TGF-), epidermal (EGF), etc.) endogenous mediators that affect proliferation keratinocytes and cause rapid Currently, question para...

BACKGROUND A cross-sectional survey was conducted between April 1995 and March 1996 to investigate arsenic-associated skin lesions of keratosis and hyperpigmentation in West Bengal, India, and to determine their relationship to arsenic water levels. METHODS In all, 7683 participants were examined and interviewed, and the arsenic levels in their drinking water measured. RESULTS Although wate...

Background: The objective of this study was to identify the molecular processes responsible for the anti-lesional activity of imiquimod in subjects with actinic keratosis using global gene expression profiling. Methods: A double-blind, placebo-controlled, randomized study was conducted to evaluate gene expression changes in actinic keratosis treated with imiquimod 5% cream. Male subjects (N = 1...